This is a featured episode from an educational podcast series with expert discussions on antibody drug conjugates, intended for US healthcare professionals.

Hosted by Dr Javier Cortés and Prof. Peter Schmid, joined by an international panel of experts in ADCs and breast cancer, this educational podcast series unveils invaluable insights into ADCs.

Throughout this podcast series our experts delve into crucial topics surrounding ADCs in breast cancer, shedding light on their developmental history, discussing their distinctive structural features and mechanisms of action, and exploring potential future advancements of ADCs.

CHAIR: Prof. Peter Schmid, FRCP, MD, PhD, Centre for Experimental Cancer Medicine, Barts Cancer Institute, UK.

SPEAKERS: Dr Christine Brezden-Masley, Practicing Medical Oncologist and Division Head of Hematology / Oncology, St. Michael’s Hospital in Toronto, Co-Director of the Hematology/Oncology Clinical Research Group and Dr Kevin Kalinsky, Associate Professor in the Department of Hematology and Medical Oncology, Emory University School of Medicine, Director of the Glenn Family Breast Center at Winship.

Chairs and speakers involved in this podcast series received honorarium from Gilead Sciences, Inc. for their contributions.

The information presented in this podcast episode is up to date as of March 2024 and may be subject to change.

View the full series from Gilead Sciences, Inc.

This is a non-promotional educational podcast series dedicated to US healthcare professionals only. This podcast series was funded and produced by Gilead Sciences, Inc. © 2025 Gilead Sciences, Inc. All rights reserved. GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. Intended for US healthcare professionals only.

Gilead Sciences, Inc.

Articles

ADC Cast: ADC antigen targets: What are we aiming at?